Long-term follow-up of psilocybin-facilitated smoking cessation
Top Cited Papers
- 21 July 2016
- journal article
- clinical trial
- Published by Taylor & Francis in The American Journal of Drug and Alcohol Abuse
- Vol. 43 (1), 55-60
- https://doi.org/10.3109/00952990.2016.1170135
Abstract
Background: A recent open-label pilot study (N = 15) found that two to three moderate to high doses (20 and 30 mg/70 kg) of the serotonin 2A receptor agonist, psilocybin, in combination with cognitive behavioral therapy (CBT) for smoking cessation, resulted in substantially higher 6-month smoking abstinence rates than are typically observed with other medications or CBT alone. Objectives: To assess long-term effects of a psilocybin-facilitated smoking cessation program at ≥12 months after psilocybin administration. Methods: The present report describes biologically verified smoking abstinence outcomes of the previous pilot study at ≥12 months, and related data on subjective effects of psilocybin. Results: All 15 participants completed a 12-month follow-up, and 12 (80%) returned for a long-term (≥16 months) follow-up, with a mean interval of 30 months (range = 16–57 months) between target-quit date (i.e., first psilocybin session) and long-term follow-up. At 12-month follow-up, 10 participants (67%) were confirmed as smoking abstinent. At long-term follow-up, nine participants (60%) were confirmed as smoking abstinent. At 12-month follow-up 13 participants (86.7%) rated their psilocybin experiences among the five most personally meaningful and spiritually significant experiences of their lives. Conclusion: These results suggest that in the context of a structured treatment program, psilocybin holds considerable promise in promoting long-term smoking abstinence. The present study adds to recent and historical evidence suggesting high success rates when using classic psychedelics in the treatment of addiction. Further research investigating psilocybin-facilitated treatment of substance use disorders is warranted.Keywords
Funding Information
- National Institute on Drug Abuse (R01DA003889)
- Beckley Foundation (N/A)
- Heffter Research Institute (N/A)
This publication has 23 references indexed in Scilit:
- Validation of the revised Mystical Experience Questionnaire in experimental sessions with psilocybinJournal of Psychopharmacology, 2015
- Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addictionJournal of Psychopharmacology, 2014
- Pharmacological Treatments for Smoking CessationJAMA, 2014
- Factor Analysis of the Mystical Experience Questionnaire: A Study of Experiences Occasioned by the Hallucinogen PsilocybinJournal for the Scientific Study of Religion, 2012
- Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effectsPsychopharmacology, 2011
- Behavioural interventions for smoking cessation: a meta-analysis of randomized controlled trialsEuropean Heart Journal, 2008
- Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months laterJournal of Psychopharmacology, 2008
- Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significancePsychopharmacology, 2006
- Cut‐off levels for breath carbon monoxide as a marker for cigarette smokingAddiction, 2005
- Timeline Follow-BackPublished by Springer Nature ,1992